Ajanta Pharma climbs after USFDA approval

The pharma company has announced that it has received US FDA nod for Almotriptan Malate tablets.

Ajanta Pharma climbed 2.9% to Rs.1437 on BSE. The pharma company has announced that it has received US FDA nod for Almotriptan Malate tablets.

The scrip opened at Rs. 1421 and has touched a high and low of Rs. 1448.8 and Rs. 1420 respectively. So far 82348(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 12295.53 crore.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720 on 12-Aug-2015 and a 52 week low of Rs. 1090 on 23-Mar-2015. Last one week high and low of the scrip stood at Rs. 1415.95 and Rs. 1274 respectively.

The promoters holding in the company stood at 73.78 % while Institutions and Non-Institutions held 10.76 % and 15.46 % respectively.

The stock is currently trading below its 200 DMA.